GlassScriptPhysician profile
Bridget Olivia Corey
NPI 1205199296
$3,577.81
in general payments reported to CMS, 2019-2025
29 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $177 · 2021: $377 · 2022: $669 · 2023: $741 · 2024: $729 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $898.43 | 2019-2025 | Grafix Pl, Stravix, Collagenase Santyl |
| Organogenesis INC. | $482.01 | 2021-2025 | Puraply Antimicrobial, Apligraf, Puraply Wound Matrix |
| Paratek Pharmaceuticals, INC. | $473.34 | 2021-2025 | Nuzyra |
| Tactile Systems Technology INC | $466.85 | 2020-2024 | Entre Plus, Flexitouch Plus |
| Abbott Laboratories | $122.72 | 2022-2023 | Octrode |
| Horizon Therapeutics Plc | $113.36 | 2019-2022 | |
| Bioventus LLC | $100.82 | 2022-2024 | Exogen Ultrasound Bone Healing System, Stimrouter Implantable Kit, Exogen Ultrasound Bone Healing System |
| Ani Pharmaceuticals, INC. | $92.83 | 2023-2024 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $84.80 | 2023-2025 | Qutenza |
| Treace Medical Concepts, INC. | $69.01 | 2024-2025 | |
| Grt US Holding, INC. | $68.45 | 2021-2022 | |
| Nevro Corp. | $61.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $57.18 | 2025 | |
| Amgen INC. | $55.07 | 2024 | Krystexxa |
| Convatec INC. | $52.52 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $46.42 | 2021 | |
| Kerecis Limited | $46.30 | 2020-2022 | |
| Celularity INC. | $33.42 | 2020 | |
| Trice Medical, INC. | $32.84 | 2024 | |
| Medtronic, INC. | $31.64 | 2022-2023 | Intellis Adaptivestim |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.46 | 2021-2022 | |
| Pfizer INC. | $30.08 | 2019 | |
| Depuy Synthes Sales INC. | $23.57 | 2019 | |
| Integra Lifesciences Corporation | $20.70 | 2023 | Tcc-Ez |
| Ironshore Pharmaceuticals INC. | $19.00 | 2020 | |
| Amniox Medical, INC. | $17.15 | 2020 | |
| Abbvie INC. | $17.08 | 2025 | |
| Lifenet Health | $15.26 | 2023 | |
| Misonix INC | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Corey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.